NCT02998385View on ClinicalTrials.gov

Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

January 20, 2017

Primary Completion Date

February 28, 2030

Study Completion Date

March 31, 2030

Conditions
HNSCC
Interventions
DRUG

Cisplatin

intravenous, concomitant to irradiation

RADIATION

radiotherapy

66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week

Trial Locations (1)

94

Hôpital Bégin, Saint-Mandé

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

lead

Groupe Oncologie Radiotherapie Tete et Cou

OTHER